Findings

What do systematic reviews say?

1,514 questions · 1,543 findings · 649 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 224 · 14.5%GRADE not reported 105 · 6.8%Very low 383 · 24.8%Low 447 · 29%Moderate 293 · 19%High 91 · 5.9%

Cannabis cigarettes vs placebo

Withdrawals due to adverse events · people with active UC

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Briakinumab vs placebo

Adverse events (Panaccione 2010) · induction of remission in Crohn's disease

Briakinumab showed no clear difference in adverse events (Panaccione 2010) compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.9 [0.75, 1.07]
1 study · 230 participants
Moderate

CHRONIC: ACEi or ARB vs placebo

Treatment related adverse events · Patients undergoing any type of surgery under general anaesthesia receiving ACEIs or ARBs perioperatively

1 finding from 1 review

Perioperative angiotensin‐converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing… 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 385 participants
Very low

Budesonide 15 mg vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.55 [0.45, 5.34]
2 studies · 181 participants
Low

Budesonide 3 mg vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.66 [0.11, 3.8]
1 study · 133 participants
Low

Budesonide 9 mg vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.14 [0.46, 2.79]
3 studies · 379 participants
Low

Chondroitin vs placebo

Number of serious adverse events · patients with osteoarthritis

Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
OR 0.4 [0.19, 0.82]
6 studies · 954 participants
Moderate

Budesonide MMX® 6 mg vs placebo

Withdrawals due to adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.1 [0.55, 2.22]
2 studies · 512 participants
Low

Capsaicin vs placebo

Treatment‐related adverse events · non‐allergic rhinitis

The review found no eligible studies for this question.

1 finding from 1 review

Capsaicin for non‐allergic rhinitis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

COX‐2 NSAIDs vs placebo

Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)

COX‐2 NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… 2015 · Cochrane Headline outcomes only
RR 0.92 [0.14, 6.21]
669 participants
Moderate

Traditional NSAIDs vs placebo

Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)

Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… 2015 · Cochrane Headline outcomes only
RR 1.69 [0.36, 7.97]
671 participants
Moderate

Diacerein vs placebo

Withdrawals due to adverse events · patients with osteoarthritis

Diacerein showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Diacerein for osteoarthritis 2014 · Cochrane Headline outcomes only
RR 1.29 [0.83, 2.01]
1476 participants
Low

Allopurinol vs placebo

Withdrawals due to adverse events · people with chronic gout

Allopurinol showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
RR 1.36 [0.61, 3.08]
2 studies · 453 participants
Moderate

Aclidinium bromide vs placebo

Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease

Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Aclidinium bromide for stable chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 0.89 [0.7, 1.14]
10 studies · 5651 participants
Moderate

Oral NSAIDs vs placebo

Withdrawals due to adverse events · Adults with lateral elbow pain

The review found no eligible studies for this question.

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical NSAIDs vs placebo

Withdrawals due to adverse events · Adults with lateral elbow pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 185 participants
Low

Pregabalin vs placebo at end of treatment

Withdrawals due to adverse events · patients with fibromyalgia

Pregabalin leads to higher withdrawal due to adverse events compared with placebo at end of treatment (high certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.68 [1.36, 2.07]
5 studies · 3259 participants
High

Nefopam 60 mg tds vs placebo

Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis

Nefopam 60 mg tds showed no clear difference in withdrawal Due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Neuromodulators for pain management in rheumatoid arthritis 2012 · Cochrane Headline outcomes only
RR 11 [0.64, 189.65]
1 study · 54 participants
Moderate

Oromucosal cannabis (Sativex) vs placebo

Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis

Oromucosal cannabis (Sativex) showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Neuromodulators for pain management in rheumatoid arthritis 2012 · Cochrane Headline outcomes only
RR 0.13 [0.01, 2.39]
1 study · 58 participants
Low

IL‐10 vs placebo

Withdrawls due to adverse events · induction of remission in Crohn's disease

IL‐10 probably leads to higher withdrawls due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant human interleukin 10 for induction of remission in Crohn's disease 2010 · Cochrane Headline outcomes only
RR 13.5 [3.89, 46.79]
2 studies · 228 participants
Moderate